Nuvalent, Inc.
nuvalent.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q1 FY2026 10-Q, filed May 7, 2026. Its latest SEC filing is a 15-12G from Jul 27, 2026.
10-Q for Q1 FY2026, filed May 7, 2026
The sections below describe the company as of the FY2025 annual report.
What Did They Do?
Develops precisely targeted small-molecule therapies for patients with cancer, including lung cancer and other solid tumors.
10-K for FY2025, filed Feb 26, 2026We are a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. We leverage…View ↗
Our first lead product candidate, zidesamtinib (NVL-520), is being developed for patients with ROS proto-oncogene 1 (ROS1)-positive…View ↗
Our second lead product candidate, neladalkib (NVL-655), is being developed for patients with anaplastic lymphoma kinase (ALK)-positive…View ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q1 FY2026, filed May 7, 2026
−$109.3MView ↗
- ▲ +29% (Loss)
- vs −$84.6M in Q1 FY2025
-
Jul 15, 2026
GSK completed its acquisition of Nuvalent
The merger closed, making Nuvalent a direct wholly owned subsidiary of Parent.
Sources
8-K, filed Jul 15, 2026
As described in the Introductory Note above, on July 15, 2026, Purchaser irrevocably accepted for payment all Shares that were validly…View ↗
-
Jun 9, 2026
Nuvalent agreed to be acquired by GSK
The agreement provided for a cash tender offer for all Nuvalent shares, followed by a merger if conditions were met.
Sources
8-K, filed Jun 9, 2026
On June 9, 2026, Nuvalent, Inc., a Delaware corporation (the “Company” or “Nuvalent”), entered into an Agreement and Plan of Merger (the…View ↗
Who Did They Compete With?
Competes with Pfizer, Roche, Bristol-Myers Squibb, Nuvation Bio, Novartis, Chugai Pharmaceutical, Takeda Pharmaceutical, Xcovery Holdings, Boehringer Ingelheim, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo, and AstraZeneca
10-K for FY2025, filed Feb 26, 2026approved kinase inhibitors, including FDA-approved ROS1 TKIs (Xalkori, Rozlytrek, Augtyro, and Ibtrozi marketed by Pfizer, Roche…View ↗
Loading...
